×
News Home

Is Inflarx NV (IFRX) a Stock to Watch After Losing -25.84% This Week?

Friday, February 26, 2021 10:43 AM | InvestorsObserver Analysts
Is Inflarx NV (IFRX) a Stock to Watch After Losing -25.84% This Week?

Inflarx NV (IFRX) stock has fallen 25.84% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bearish
Inflarx NV has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IFRX!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With IFRX Stock Today?

Inflarx NV (IFRX) stock is trading at $4.19 as of 10:42 AM on Friday, Feb 26, a drop of -$0.30, or -6.68% from the previous closing price of $4.49. The stock has traded between $4.15 and $4.56 so far today. Volume today is low. So far 254,002 shares have traded compared to average volume of 401,342 shares.

To screen for more stocks like Inflarx NV click here.

More About Inflarx NV

InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Click Here to get the full Stock Score Report on Inflarx NV (IFRX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App